Publication | Closed Access

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer TreatmentAnti-il-6r Monoclonal AntibodyOncologyRadiation OncologyOvarian Cancer